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In a recent issue of the European Respiratory Journal we read with interest the article by COTE et al. [1] on the capacity of the 6-min walk distance to predict mortality in chronic obstructive pulmonary disease patients. We noted a striking difference between the cut-off value reported by COTE et al. [1] , corresponding to 350 m, and a cut-off value previously reported as the mortality predictor in patients with idiopathic pulmonary fibrosis, which was 207 m [2] .
Even considering the obvious diversities between the two diseases, such a difference is quite surprising. The two populations cannot be compared by forced expiratory volume in one second values because such data are lacking in the article by LEDERER et al. [2] , but in both studies there are the data concerning forced vital capacity (FVC). Thus, we are permitted to compare the lung function by this parameter, where a remarkable difference can also be found: COTE et al. [1] reported a mean FVC value of 72.7¡21% predicted, whereas LEDERER et al. [2] reported a mean value of 51¡17% pred. The mortality rates were approximately two-fold in the study by COTE et al. [1] and four-fold in the study by LEDERER et al. [2] . In particular, the mortality rates recorded by LEDERER et al. [2] were significantly lower in the fourth quintile, patients walking 314-395 m, which included the allocated 350 m cutoff reported by COTE et al. [1] .
As physicians currently working in a pulmonary rehabilitation setting we would like to learn more about the prognostic significance of the distance walked during the 6-min walk distance test in different respiratory diseases, which was not discussed in the study by COTE et al. 
From the authors:
We have read with interest the observations by G.G. Riario Sforza and C. Incorvaia regarding the differences in the threshold values used to predict mortality that were provided by LEDERER et al. [1] for patients with idiopathic pulmonary fibrosis (IPF) and those that were reported for patients with chronic obstructive pulmonary disease (COPD) [2] .
First, G.G. Riario Sforza and C. Incorvaia correctly point out that LEDERER et al. [1] quote a threshold of 207 m as being more specific for waiting-list mortality at 6 months but, in the discussion, LEDERER et al. [1] also state that the 350-m cut-off remained more sensitive for waiting-list mortality, a value that is very close to the one we reported [2] .
Secondly, G.G. Riario Sforza and C. Incorvaia show surprise about the difference in mortality between the patients with IPF and those with COPD in our study. This has several likely explanations. To begin with, the patients reported by LEDERER et al. [1] were all on the waiting list for transplantation due to IPF, whereas ours were patients with different severity of COPD attending regular clinics, that is to say, healthier [2] . Furthermore, LEDERER et al. [1] do not mention the use of corticosteroids or immunosuppressants in their patients but it is very likely that patients with such severity of IPF may have been on agents capable of inducing muscle dysfunction. Finally, patients with COPD, even on transplant lists, have a better prognosis than patients with IPF or other underlying disease, thereby making direct comparisons difficult.
